Pasithea Therapeutics Corp. Form 8-K Summary
Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K regarding shareholder director nominations and proposals. The earliest reported event occurred on October 6, 2023; the report was signed on October 13, 2023. The company is an emerging growth company listed on Nasdaq under KTTA and KTTAW.
Annual Meeting and Shareholder Deadlines
- The 2023 annual meeting of stockholders is scheduled for November 29, 2023.
- Proxy materials were expected to begin being delivered or made available on or about October 23, 2023.
- Stockholder proposals intended for inclusion under Exchange Act Rule 14a-8 had to be received by October 23, 2023 and comply with applicable Rule 14a-8 requirements.
- Director nominations and other proposals under the company’s amended and restated bylaws also had to be submitted by October 23, 2023.
- Stockholders soliciting proxies in support of director nominees other than the company’s nominees had to provide the notice required by Rule 14a-19 by October 23, 2023.
Financial Metrics and Material Changes
This filing does not report revenue, profit or loss, cash flow, margins, debt, liquidity, operating performance, financial guidance, or other financial metrics. It does not disclose a material change in the company’s financial condition or results of operations.
Outlook, Risks, and Unusual Items
The filing concerns annual-meeting procedures rather than business operations or financial outlook. No new guidance, management forecast, material contingency, litigation matter, financing, or unusual accounting item is disclosed.
Important Facts for Investors to Verify
- Confirm the November 29, 2023 annual meeting date and the October 23, 2023 deadline for proposals, nominations, and Rule 14a-19 notices.
- Review the company’s proxy materials for the meeting agenda, director nominees, voting matters, and any subsequent changes.
- Review the company’s latest periodic filings separately for cash runway, financing needs, operating losses, liquidity, and development risks, none of which are addressed in this 8-K.